
## Jennifer N Clements

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8345173/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clinical Pharmacokinetics, 2018, 57, 1529-1538.	1.6	39
2	What's new in multiple sclerosis?. Mental Health Clinician, 2017, 7, 213-220.	0.5	30
3	Burnout among clinical pharmacists: Causes, interventions, and a call to action. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 832-842.	0.5	19
4	<p>Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 505-512.	1.1	14
5	Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 390-405.	0.5	12
6	Clinical review of subcutaneous semaglutide for obesity. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 184-193.	0.7	12
7	Glucagon: Its evolving role in the management of hypoglycemia. Pharmacotherapy, 2021, 41, 623-633.	1.2	10
8	Clinical review and role of clinical pharmacists in obesity management: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1469-1484.	0.5	4
9	Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus. Clinical Pharmacokinetics, 2021, 60, 153-163.	1.6	3
10	A cross-sectional study of student pharmacists' attitudes and self-awareness towards obesity and weight. Currents in Pharmacy Teaching and Learning, 2021, 13, 1654-1658.	0.4	2
11	To Heart "Fail―or Not? The Expanding Role of SGLT2 Inhibitors. ADCES in Practice, 2021, 9, 28-33.	0.2	1
12	Person-Centered Care: Are We Doing It?. ADCES in Practice, 2021, 9, 34-37.	0.2	1
13	Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, 593-604.	0.8	1
14	A guide for the pharmacist's role in insulin pump management during transitions of care. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 352-363.	0.5	1
15	Choose Your Words Wisely: The Language of Diabetes. ADCES in Practice, 2020, 8, 40-41.	0.2	0
16	Brief Literature Review: Glycemic Control With Ketogenic Diet in People With Diabetes. Diabetes Spectrum, 2021, 34, ds200037.	0.4	0
17	Got Glucagon? Update on New Formulations to Treat Hypoglycemia. ADCES in Practice, 2021, 9, 60-63.	0.2	0
18	Evidence-Based Management of Steroid-Induced Hyperglycemia in the Inpatient Setting. ADCES in Practice, 2022, 10, 40-45.	0.2	0

#	Article	IF	CITATIONS
19	Glucagon and Its Underutilization in Diabetes Self-Management: A Teachable Moment. Clinical Diabetes, 0, , .	1.2	0